UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 8, 2010
WRIGHT MEDICAL GROUP, INC.
(Exact name of registrant as specified in charter)
| |
|
|
|
|
| Delaware
|
|
000-32883
|
|
13-4088127 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number) |
| |
|
|
| 5677 Airline Road, Arlington, Tennessee
|
|
38002 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (901) 867-9971
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01. Other Events.
Foreign Corrupt Practices Act Investigation
As previously disclosed, in June 2008 we received a letter from the Securities and Exchange
Commission informing us that it was conducting an informal investigation regarding potential
violations of the Foreign Corrupt Practices Act in the sale of medical devices in a number of
foreign countries by companies in the medical device industry. We have been advised by the
Commission’s Division of Enforcement, that this investigation has been completed as to us and that
the Division of Enforcement does not intend to recommend any enforcement action by the Commission
against us.
1